The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Viracept
Synonyms :
Class :
HIV, Protease Inhibitors
Brand Name :
Viracept
Synonyms :
Class :
HIV, Protease Inhibitors
Dosage Forms & Strengths Â
Tablet Â
250mg Â
625mg Â
1250
mg
Orally 
every 12 hrs a day
or 750 mg orally every 8 hours a day
1250
mg
orally
every 12 hrs
a day or 750 mg orally every 8 hours a day for 28 days
Dosage Forms & Strengths Â
Tablet Â
250mg Â
625mg Â
Age: 2-13 years
45-55 mg/kg orally every 12 hours a day or 25-35 mg/kg orally every 8 hours a day
Adolescents:
1250 mg orally every 12 hours a day or 750 mg orally every 8 hours a day
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
nelfinavir: they may enhance serum concentrations of rifabutin
nelfinavir has the potential to enhance the level or impact of intranasal dihydroergotamine intranasal by modulating the hepatic/intestinal enzyme CYP3A4 metabolism
may have an increased QTc-prolonging effect when combined with arsenic trioxide
azithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clofazimine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc-prolonging agents: they may increase the QTc-prolonging effect of clomipramine
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
ondansetron: they may increase the QTc-prolonging effect of QTc-prolonging Agents
oxytocin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
afatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
calcium chloride: it may increase the risk or severity of QTc prolongation
calcium gluconate: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
It may enhance when combined with oxycodone by affecting CYP3A4 metabolism
nelfinavir: they may enhance the serum concentration of amiodarone
when both drugs are combined, there may be a reduced metabolism of vincristine  
the effect of nelfinavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nelfinavir 
nelfinavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
nelfinavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of dronabinol by altering the intestinal or hepatic metabolism
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the risk of sedation
may increase the risk of sedation
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with moxifloxacin
may increase the QTc-prolonging action of QT-prolonging agents (Highest Risk)
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
it may decrease the serum concentration of Estrogen Derivatives
bazedoxifene/conjugated estrogens
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
it may diminish the metabolism when combined with azelastine
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
when both drugs are combined, there may be a decreased metabolism of etoposide   
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
it may increase the toxicity of each other
may diminish the serum concentration
QTc-prolongers increase the effect of levoketoconazole
may increase the QTc-prolonging effects of QTc-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration of estrogen derivatives
may diminish the amount of P-glycoprotein (MDR1) efflux transporter
QT-prolonging Miscellaneous Agents may increase the QTc-prolonging effect of chloroquine
QT-prolonging agents increase the effect of haloperidol
nelfinavir has the potential to modify the metabolism of propoxyphene, resulting in increased levels of propoxyphene in the bloodstream
azatadine: it may increase the risk or severity of QTc prolongation
calcium acetate: it may increase the risk or severity of QTc prolongation
gallopamil: it may increase the risk or severity of QTc prolongation
berotralstat: it may increase the risk or severity of QTc prolongation agents
betahistine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
bilastine: it may increase the risk or severity of QTc prolongation agents
bisoprolol: it may increase the risk or severity of QTc prolongation agents
bisoxatin: it may increase the risk or severity of QTc prolongation agents
amikacin: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
bendamustine: it may increase the risk or severity of QTc prolongation agents
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
nelfinavir, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
QT-prolonging other agents (highest Risk) may intensify amiodarone's QTc-prolonging action
QT-prolonging agents (highest Risk) may increase clofazimine's ability to prolong QTc
Adverse drug reactions:  Â
>10% Â
Diarrhea (14-20%) Â
1-10% Â
Rash (1-3%) Â
Impaired concentration (1%) Â
Lipodystrophy (1%) Â
Leukopenia (1%) Â
Nausea (3-7%) Â
Flatulence (1-5%) Â
Abdominal pain (1%) Â
Thrombocytopenia (1%) Â
Weakness (1%) Â
Anemia (1%) Â
Allergic reaction (1%) Â
Metabolic acidosis (1%) Â
<1% Â
Diabetes mellitus Â
QTc prolongation Â
Hyperglycemia Â
  Â
 Â
Pregnancy warnings:    Â
AU TGA pregnancy category: B2Â
US FDA pregnancy category: BÂ
Lactation:Â
Excreted into human milk is UNknown Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.      Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this categoryÂ
 Â
Patient Information Leaflet   Â
Generic Name: nelfinavirÂ
Why do we use nelfinavir?Â
nelfinavir is an HIV, Protease Inhibitors used to treat HIV Infection Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
